Tillman Gerngross, Adagio Therapeutics CEO

GV steps up to back Till­man Gern­gross’ new an­ti­body play against Covid-19 — and he’s al­ready think­ing about the IPO

Till­man Gern­gross had two good rea­sons to cel­e­brate on Mon­day.

First, he felt that Pfiz­er’s up­beat as­sess­ment of its piv­otal Covid-19 vac­cine da­ta marked an un­prece­dent­ed break­through in the speed of vac­cine de­vel­op­ment and a “big day” for sci­ence as a whole.

Sec­ond, he was ready to of­fer me a pre­view of an $80 mil­lion round de­signed to pro­pel his new biotech start­up — Ada­gio Ther­a­peu­tics — to­ward an IPO next year as it ramps up what he be­lieves can be a con­tender for the most pow­er­ful an­ti­body avail­able to com­bat a virus that has re­peat­ed­ly rat­tled the globe with waves of ris­ing in­fec­tion and death rates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.